| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
SNTI
Senti Biosciences
|
Dec 15, 2025 | BUY |
Strong Buy
+835.9% avg upside
7 analysts
|
— | -21.4% |
|
PYXS
Pyxis Oncology
|
Aug 15, 2025 | BUY |
Strong Buy
+244.6% avg upside
13 analysts
|
$7.00
244.75% Upside
|
+54.5% |
|
JANX
Janux Therapeutics Inc
|
Aug 12, 2025 | BUY |
Strong Buy
+217.9% avg upside
21 analysts
|
$87.00
511.91% Upside
|
-41.7% |
|
MRK
Merck & Company
|
Oct 28, 2022 | BUY |
Strong Buy
+10.7% avg upside
43 analysts
|
$112.00
1.72% Downside
|
+9.1% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.